Aminopeptidase N (CD13) as a target for cancer chemotherapy

The enzyme aminopeptidase N (APN, also known as CD13) is a Zn2+ dependent membrane‐bound ectopeptidase that degrades preferentially proteins and peptides with a N‐terminal neutral amino acid. Aminopeptidase N has been associated with the growth of different human cancers and suggested as a suitable target for anti‐cancerous therapy. Different approaches have been used to develop new drugs directed to this target, including enzyme inhibitors as well as APN‐targeted carrier constructs. This review discusses the prevalence and possible function of APN in malignant diseases, mainly solid tumors, as well as its “drugability” evaluated in preclinical in vivo models, and also provides a brief overview of current clinical trials focused on APN. (Cancer Sci 2011; 102: 501–508)

[1]  Zu-hua Gao,et al.  LYP, a novel bestatin derivative, inhibits cell growth and suppresses APN/CD13 activity in human ovarian carcinoma cells more potently than bestatin , 2011, Investigational New Drugs.

[2]  J. Cortes,et al.  The OPAL study: A phase II study to evaluate the efficacy, safety, and tolerability of tosedostat (CHR-2797) in elderly subjects with treatment refractory or relapsed acute myeloid leukemia. , 2010 .

[3]  G. Ceresoli,et al.  Phase II study of asparagine-glycine-arginine-human tumor necrosis factor alpha, a selective vascular targeting agent, in previously treated patients with malignant pleural mesothelioma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  R. Lewensohn,et al.  The alkylating prodrug J1 can be activated by aminopeptidase N, leading to a possible target directed release of melphalan. , 2010, Biochemical pharmacology.

[5]  Leaf Huang,et al.  Nanoparticles targeted with NGR motif deliver c-myc siRNA and doxorubicin for anticancer therapy. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[6]  P. Scifo,et al.  Defining the optimal biological dose of NGR-hTNF, a selective vascular targeting agent, in advanced solid tumours. , 2010, European journal of cancer.

[7]  H. Wada,et al.  Stromal aminopeptidase N expression: correlation with angiogenesis in non-small-cell lung cancer , 2009, General thoracic and cardiovascular surgery.

[8]  Qiang Zhang,et al.  NGR-modified micelles enhance their interaction with CD13-overexpressing tumor and endothelial cells. , 2009, Journal of controlled release : official journal of the Controlled Release Society.

[9]  A. Harris,et al.  A First-in-Man Phase I and Pharmacokinetic Study on CHR-2797 (Tosedostat), an Inhibitor of M1 Aminopeptidases, in Patients with Advanced Solid Tumors , 2009, Clinical Cancer Research.

[10]  C. Punt,et al.  Phase Ib study of NGR–hTNF, a selective vascular targeting agent, administered at low doses in combination with doxorubicin to patients with advanced solid tumours , 2009, British Journal of Cancer.

[11]  Walter Heindel,et al.  Infarction of tumor vessels by NGR-peptide-directed targeting of tissue factor: experimental results and first-in-man experience. , 2009, Blood.

[12]  D. Ribatti,et al.  Enhanced Antitumor Efficacy of Clinical-Grade Vasculature-Targeted Liposomal Doxorubicin , 2008, Clinical Cancer Research.

[13]  Xiaopan Zhang,et al.  Aminopeptidase N (APN/CD13) as a target for anti-cancer agent design. , 2008, Current medicinal chemistry.

[14]  Gary Box,et al.  CHR-2797: an antiproliferative aminopeptidase inhibitor that leads to amino acid deprivation in human leukemic cells. , 2008, Cancer research.

[15]  P. Mina-Osorio.  The moonlighting enzyme CD13: old and new functions to target , 2008, Trends in Molecular Medicine.

[16]  A. Corti,et al.  Vasculature‐targeted tumor necrosis factor‐alpha increases the therapeutic index of doxorubicin against prostate cancer , 2008, The Prostate.

[17]  W. Berdel,et al.  Generation of fusion proteins for selective occlusion of tumor vessels. , 2008, Current drug discovery technologies.

[18]  B. Seliger,et al.  Aminopeptidase N (APN)/CD13-dependent CXCR4 downregulation is associated with diminished cell migration, proliferation and invasion , 2008, Molecular membrane biology.

[19]  S. Lippard,et al.  Conjugated platinum(IV)-peptide complexes for targeting angiogenic tumor vasculature. , 2008, Bioconjugate chemistry.

[20]  W. Heindel,et al.  In vivo optical imaging of CD13/APN-expression in tumor xenografts. , 2008, Journal of biomedical optics.

[21]  H. Lindman,et al.  The novel alkylating prodrug J1: diagnosis directed activity profile ex vivo and combination analyses in vitro , 2008, Investigational New Drugs.

[22]  Fumitaka Kikkawa,et al.  Aminopeptidase N (APN)/CD13 inhibitor, Ubenimex, enhances radiation sensitivity in human cervical cancer , 2008, BMC Cancer.

[23]  L. Shapiro,et al.  CD13/APN transcription is regulated by the proto-oncogene c-Maf via an atypical response element. , 2007, Gene.

[24]  S. Rabbani,et al.  Binding and internalization of NGR-peptide-targeted liposomal doxorubicin (TVT-DOX) in CD13-expressing cells and its antitumor effects , 2007, Anti-cancer drugs.

[25]  R. Lewensohn,et al.  The novel melphalan prodrug J1 inhibits neuroblastoma growth in vitro and in vivo , 2007, Molecular Cancer Therapeutics.

[26]  H. Kajiyama,et al.  Involvement of aminopeptidase N in enhanced chemosensitivity to paclitaxel in ovarian carcinoma in vitro and in vivo , 2007, International journal of cancer.

[27]  Wenfang Xu,et al.  The structure and main functions of aminopeptidase N. , 2007, Current medicinal chemistry.

[28]  J. Irazusta,et al.  Altered levels of acid, basic, and neutral peptidase activity and expression in human clear cell renal cell carcinoma. , 2007, American journal of physiology. Renal physiology.

[29]  M. Imamura,et al.  Clinicopathological significance of aminopeptidase N/CD13 expression in human gastric carcinoma. , 2007, Hepato-gastroenterology.

[30]  K. Nishikawa,et al.  Aminopeptidase N (APN/CD13) is selectively expressed in vascular endothelial cells and plays multiple roles in angiogenesis. , 2006, Cancer letters.

[31]  Chiara Brignole,et al.  Targeting liposomal chemotherapy via both tumor cell-specific and tumor vasculature-specific ligands potentiates therapeutic efficacy. , 2006, Cancer research.

[32]  M. Higashiyama,et al.  Clinical Significance of Aminopeptidase N in Non–Small Cell Lung Cancer , 2006, Clinical Cancer Research.

[33]  Quynh-Thu Le,et al.  Non-small cell lung cancer: Clinical practice guidelines in oncology , 2006 .

[34]  M. Schwartz,et al.  Matrix metalloproteinase inhibitors as prospective agents for the prevention and treatment of cardiovascular and neoplastic diseases. , 2006, Current topics in medicinal chemistry.

[35]  M. Dietel,et al.  Expression of aminopeptidase N/CD13 in human ovarian cancers , 2006, International Journal of Gynecologic Cancer.

[36]  A. Corti,et al.  Synergistic Antitumor Activity of Cisplatin, Paclitaxel, and Gemcitabine with Tumor Vasculature-Targeted Tumor Necrosis Factor-α , 2006, Clinical Cancer Research.

[37]  B. Bauvois,et al.  Aminopeptidase‐N/CD13 (EC 3.4.11.2) inhibitors: Chemistry, biological evaluations, and therapeutic prospects , 2005, Medicinal research reviews.

[38]  N. Kohno,et al.  Circulating Aminopeptidase N/CD13 Is an Independent Prognostic Factor in Patients with Non–Small Cell Lung Cancer , 2005, Clinical Cancer Research.

[39]  S. Ramakrishnan,et al.  Addition of an aminopeptidase N‐binding sequence to human endostatin improves inhibition of ovarian carcinoma growth , 2005, Cancer.

[40]  R. Cristiano,et al.  Tumor-specific gene delivery mediated by a novel peptide-polyethylenimine-DNA polyplex targeting aminopeptidase N/CD13. , 2005, Human gene therapy.

[41]  Zhouen Zhang,et al.  A New Class of 5-Fluoro-2′-deoxyuridine Prodrugs Conjugated with a Tumor-Homing Cyclic Peptide CNGRC by Ester Linkers: Synthesis, Reactivity, and Tumor-Cell–Selective Cytotoxicity , 2005, Pharmaceutical Research.

[42]  A. Corti,et al.  Tumor Vascular Targeting with Tumor Necrosis Factor α and Chemotherapeutic Drugs , 2004 .

[43]  K. Luthman,et al.  Antitumor efficacy and acute toxicity of the novel dipeptide melphalanyl-p-L-fluorophenylalanine ethyl ester (J1) in vivo , 2004, Investigational New Drugs.

[44]  Yasufumi Sato.  Role of aminopeptidase in angiogenesis. , 2004, Biological & pharmaceutical bulletin.

[45]  P. V. van Diest,et al.  Reduced Growth, Increased Vascular Area, and Reduced Response to Cisplatin in CD13-Overexpressing Human Ovarian Cancer Xenografts , 2004, Clinical Cancer Research.

[46]  B. Bauvois.  Transmembrane proteases in cell growth and invasion: new contributors to angiogenesis? , 2004, Oncogene.

[47]  A. Corti,et al.  Tumor vascular targeting with tumor necrosis factor alpha and chemotherapeutic drugs. , 2004, Annals of the New York Academy of Sciences.

[48]  A. Roessner,et al.  Inhibitory effect of antisense aminopeptidase N (APN/CD13) cDNA transfection on the invasive potential of osteosarcoma cells , 2004, Clinical & Experimental Metastasis.

[49]  I. Saiki,et al.  Inhibition of tumor invasion and extracellular matrix degradation by ubenimex (bestatin) , 2004, Clinical & Experimental Metastasis.

[50]  Michael C. Ostrowski,et al.  CD13/APN Transcription Is Induced by RAS/MAPK-mediated Phosphorylation of Ets-2 in Activated Endothelial Cells* , 2003, Journal of Biological Chemistry.

[51]  H. Dralle,et al.  Biological significance of aminopeptidase N/CD13 in thyroid carcinomas. , 2003, Cancer research.

[52]  D. Ribatti,et al.  Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy. , 2003, Cancer research.

[53]  H. Kwon,et al.  Irreversible inhibition of CD13/aminopeptidase N by the antiangiogenic agent curcumin. , 2003, Chemistry & biology.

[54]  H. Lilja,et al.  Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancer. , 2003, Journal of the National Cancer Institute.

[55]  H. Kato,et al.  Randomized double-blind placebo-controlled trial of bestatin in patients with resected stage I squamous-cell lung carcinoma. , 2003, Journal of the National Cancer Institute.

[56]  N. Hattori,et al.  Clinical significance of aminopeptidase N/CD13 expression in human pancreatic carcinoma. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[57]  L. Shapiro,et al.  The angiogenic regulator CD13/APN is a transcriptional target of Ras signaling pathways in endothelial morphogenesis. , 2003, Blood.

[58]  Yasufumi Sato.  Aminopeptidases and angiogenesis. , 2003, Endothelium : journal of endothelial cell research.

[59]  H. Verheul,et al.  Soluble aminopeptidase N/CD13 in malignant and nonmalignant effusions and intratumoral fluid. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[60]  J. Isaacs,et al.  A 5-fluorodeoxyuridine prodrug as targeted therapy for prostate cancer. , 2002, Bioorganic & medicinal chemistry letters.

[61]  T. Ørntoft,et al.  Gene expression in colorectal cancer. , 2002, Cancer research.

[62]  J. Lankelma,et al.  A doxorubicin-CNGRC-peptide conjugate with prodrug properties. , 2002, Biochemical pharmacology.

[63]  N. Kohno,et al.  Aminopeptidase N is involved in cell motility and angiogenesis: its clinical significance in human colon cancer. , 2002, Gastroenterology.

[64]  Wadih Arap,et al.  Differential binding of drugs containing the NGR motif to CD13 isoforms in tumor vessels, epithelia, and myeloid cells. , 2002, Cancer research.

[65]  V. Botbol,et al.  Bestatin as an experimental tool in mammals. , 2001, Current drug metabolism.

[66]  M. Tatematsu,et al.  Decreases of Metallothionein and Aminopeptidase N in Renal Cancer Tissues1 , 2001, Journal of biochemistry.

[67]  W. Arap,et al.  CD13/APN is activated by angiogenic signals and is essential for capillary tube formation. , 2001, Blood.

[68]  Fulvio Magni,et al.  Enhancement of tumor necrosis factor α antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13) , 2000, Nature Biotechnology.

[69]  R Pasqualini,et al.  Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. , 2000, Cancer research.

[70]  J. Martínez,et al.  Aminopeptidase activities in breast cancer tissue. , 1999, Clinical chemistry.

[71]  M. Walker,et al.  Receptor-mediated and enzyme-dependent targeting of cytotoxic anticancer drugs. , 1999, Pharmacology & therapeutics.

[72]  H. Lilja,et al.  Enzymatic activation of a doxorubicin-peptide prodrug by prostate-specific antigen. , 1998, Cancer research.

[73]  İ. Durak,et al.  Alanine aminopeptidase activities in cancerous and non-cancerous human breast tissues. , 1997, European journal of clinical chemistry and clinical biochemistry : journal of the Forum of European Clinical Chemistry Societies.

[74]  R Pasqualini,et al.  A peptide isolated from phage display libraries is a structural and functional mimic of an RGD-binding site on integrins , 1995, The Journal of cell biology.

[75]  K. Koshida,et al.  Adjuvant therapy with 5-fluoro-1-(2-tetrahydrofuryl)-2,4 (1H,3H)-pyrimidinedione (UFT) and Bestatin in patients with transitional cell carcinoma of the bladder--comparison between UFT therapy alone and UFT therapy in combination with Bestatin. , 1995, International journal of clinical pharmacology and therapeutics.

[76]  A. Harris,et al.  Expression of aminopeptidase-n (CD 13) in normal tissues and malignant neoplasms of epithelial and lymphoid origin. , 1994, Journal of clinical pathology.

[77]  A. Taylor.  Aminopeptidases: towards a mechanism of action. , 1993, Trends in biochemical sciences.

[78]  T. Tsuruo,et al.  Role of aminopeptidase N (CD13) in tumor‐cell invasion and extracellular matrix degradation , 1993, International journal of cancer.

[79]  A. Taylor.  Aminopeptidases: structure and function , 1993, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[80]  A. Look,et al.  Human aminopeptidase N is a receptor for human coronavirus 229E , 1992, Nature.

[81]  C. Tirelli,et al.  Diagnostic evaluation of alanine aminopeptidase as serum marker for detecting cancer. , 1991, Cancer biochemistry biophysics.

[82]  T. Hattori,et al.  Prospective randomized controlled study on bestatin in resectable gastric cancer. , 1991, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[83]  P. Möller,et al.  Expression of aminopeptidase N (CD13) in mesenchymal tumors. , 1990, The American journal of pathology.

[84]  T. Yasumitsu,et al.  Bestatin in resected lung cancer. A randomized clinical trial. , 1990, Acta oncologica.

[85]  H. Blomgren,et al.  Adjuvant bestatin (Ubenimex) treatment following full-dose local irradiation for bladder carcinoma. , 1990, Acta oncologica.

[86]  M. Fukuoka,et al.  Combination therapy with bestatin in inoperable lung cancer. A randomized trial. , 1990, Acta oncologica.

[87]  G. Siest,et al.  Human Aminopeptidases: A Review of the Literature , 1988, Journal of clinical chemistry and clinical biochemistry. Zeitschrift fur klinische Chemie und klinische Biochemie.

[88]  J. Katzenellenbogen,et al.  Plasmin-activated prodrugs for cancer chemotherapy. 2. Synthesis and biological activity of peptidyl derivatives of doxorubicin. , 1983, Journal of medicinal chemistry.

[89]  M. Masquelier,et al.  Amino acid and dipeptide derivatives of daunorubicin. 1. Synthesis, physicochemical properties, and lysosomal digestion. , 1980, Journal of medicinal chemistry.

[90]  J. Katzenellenbogen,et al.  Protease-activated "prodrugs" for cancer chemotherapy. , 1980, Proceedings of the National Academy of Sciences of the United States of America.